Azithramycine

Azithramycine is a lipid of Polyketides (PK) class. Azithramycine is associated with abnormalities such as Respiratory Tract Infections, Pneumonia, Lower respiratory tract infection, Infection and Nonspecific urethritis. The involved functions are known as Lysis, Selection, Genetic, Mutation, Relapse and Adaptation. Azithramycine often locates in Blood, Respiratory System, Genitourinary system, Back and Chest. The associated genes with Azithramycine are Genes, rRNA, Genome, RPL22 gene, OPRM1 gene and tryptic soy broth. The related lipids are Liposomes, Phosphatidylserines, Promega, Lipopolysaccharides and Steroids. The related experimental models are Mouse Model, Knock-out and Tissue Model.

References related to abnormalities published in J. Antimicrob. Chemother.

PMID	Journal	Published Date	Author	Title
10473232	J. Antimicrob. Chemother.	1999	Butler T et al.	Treatment of typhoid fever with azithromycin versus chloramphenicol in a randomized multicentre trial in India.
10511413	J. Antimicrob. Chemother.	1999	Jackson LA et al.	Safety and effect on anti-Chlamydia pneumoniae antibody titres of a 1 month course of daily azithromycin in adults with coronary artery disease.
11152432	J. Antimicrob. Chemother.	2001	Amsden GW and Gray CL	Serum and WBC pharmacokinetics of 1500 mg of azithromycin when given either as a single dose or over a 3 day period in healthy volunteers.
11679557	J. Antimicrob. Chemother.	2001	Ioannidis JP et al.	Meta-analysis of randomized controlled trials on the comparative efficacy and safety of azithromycin against other antibiotics for upper respiratory tract infections.
11679558	J. Antimicrob. Chemother.	2001	Contopoulos-Ioannidis DG et al.	Meta-analysis of randomized controlled trials on the comparative efficacy and safety of azithromycin against other antibiotics for lower respiratory tract infections.
11733476	J. Antimicrob. Chemother.	2001	Butler T	Effect of increased inoculum of Salmonella typhi on MIC of azithromycin and resultant growth characteristics.
11533011	J. Antimicrob. Chemother.	2001	Miyazaki S et al.	Efficacy of azithromycin, clarithromycin and beta-lactam agents against experimentally induced bronchopneumonia caused by Haemophilus influenzae in mice.
11751774	J. Antimicrob. Chemother.	2002	Firsov AA et al.	Comparative pharmacodynamics of azithromycin and roxithromycin with S. pyogenes and S. pneumoniae in a model that simulates in vitro pharmacokinetics in human tonsils.
11266417	J. Antimicrob. Chemother.	2001	Ferwerda A et al.	Efficacy, safety and tolerability of 3 day azithromycin versus 10 day co-amoxiclav in the treatment of children with acute lower respiratory tract infections.
11266420	J. Antimicrob. Chemother.	2001	Butler T et al.	In vitro effects of azithromycin on Salmonella typhi: early inhibition by concentrations less than the MIC and reduction of MIC by alkaline pH and small inocula.
11389120	J. Antimicrob. Chemother.	2001	Kurdowska A et al.	The effect of azithromycin and clarithromycin on ex vivo interleukin-8 (IL-8) release from whole blood and IL-8 production by human alveolar macrophages.
12205072	J. Antimicrob. Chemother.	2002	Kopjar B	Azithromycin is effective in patients with chronic bronchitis.
12003969	J. Antimicrob. Chemother.	2002	Kutlin A et al.	Effect of gemifloxacin on viability of Chlamydia pneumoniae (Chlamydophila pneumoniae) in an in vitro continuous infection model.
12003988	J. Antimicrob. Chemother.	2002	Rustomjee R et al.	A randomized controlled trial of azithromycin versus doxycycline/ciprofloxacin for the syndromic management of sexually transmitted infections in a resource-poor setting.
12096025	J. Antimicrob. Chemother.	2002	Butler T	Reduction of MIC of azithromycin for Salmonella typhi and Staphylococcus aureus in broth exposed to previous growth of Salmonella typhi.
12654753	J. Antimicrob. Chemother.	2003	Danesi R et al.	Comparative distribution of azithromycin in lung tissue of patients given oral daily doses of 500 and 1000 mg.
12775677	J. Antimicrob. Chemother.	2003	Zhanel GG et al.	Pharmacodynamic activity of azithromycin against macrolide-susceptible and -resistant Streptococcus pneumoniae simulating clinically achievable free serum, epithelial lining fluid and middle ear fluid concentrations.
12493814	J. Antimicrob. Chemother.	2003	Arreaza L et al.	Emergence of gonococcal strains with resistance to azithromycin in Spain.
12461037	J. Antimicrob. Chemother.	2002	Chiu LM et al.	Pharmacokinetics of intravenous azithromycin and ceftriaxone when administered alone and concurrently to healthy volunteers.
12888586	J. Antimicrob. Chemother.	2003	Dunne MW et al.	Randomized, double-blind study of the clinical efficacy of 3 days of azithromycin compared with co-amoxiclav for the treatment of acute otitis media.
10837459	J. Antimicrob. Chemother.	2000	Matute AJ et al.	Is a 5 day course of azithromycin enough for infections caused by Legionella pneumophila?
11102409	J. Antimicrob. Chemother.	2000	Nagai K et al.	In vitro development of resistance to ceftriaxone, cefprozil and azithromycin in Streptococcus pneumoniae.
10980164	J. Antimicrob. Chemother.	2000	Jonas D et al.	The effect of azithromycin on intracellular Legionella pneumophila in the Mono Mac 6 cell line at serum concentrations attainable in vivo.
10882684	J. Antimicrob. Chemother.	2000	Koch CC et al.	Apoptosis, oxidative metabolism and interleukin-8 production in human neutrophils exposed to azithromycin: effects of Streptococcus pneumoniae.
15163653	J. Antimicrob. Chemother.	2004	Wyrick PB and Knight ST	Pre-exposure of infected human endometrial epithelial cells to penicillin in vitro renders Chlamydia trachomatis refractory to azithromycin.
15215227	J. Antimicrob. Chemother.	2004	Drago L et al.	Selection of resistance of telithromycin against Haemophilus influenzae, Moraxella catarrhalis and streptococci in comparison with macrolides.
14963065	J. Antimicrob. Chemother.	2004	Gross M et al.	Oral anti-pneumococcal activity and pharmacokinetic profiling of a novel peptide deformylase inhibitor.
21059616	J. Antimicrob. Chemother.	2011	Muto C et al.	Pharmacokinetic-pharmacodynamic analysis of azithromycin extended release in Japanese patients with common respiratory tract infectious disease.
21393178	J. Antimicrob. Chemother.	2011	Cai Y et al.	Effectiveness and safety of macrolides in cystic fibrosis patients: a meta-analysis and systematic review.
21081549	J. Antimicrob. Chemother.	2011	Roberts MC et al.	Characterization of macrolide resistance genes in Haemophilus influenzae isolated from children with cystic fibrosis.
18931390	J. Antimicrob. Chemother.	2009	Ishimoto H et al.	Different effects of telithromycin on MUC5AC production induced by human neutrophil peptide-1 or lipopolysaccharide in NCI-H292 cells compared with azithromycin and clarithromycin.
19357159	J. Antimicrob. Chemother.	2009	Starnino S and Stefanelli P	Azithromycin-resistant Neisseria gonorrhoeae strains recently isolated in Italy.
19468025	J. Antimicrob. Chemother.	2009	Chisholm SA et al.	Emergence of high-level azithromycin resistance in Neisseria gonorrhoeae in England and Wales.
20022937	J. Antimicrob. Chemother.	2010	Biswas S et al.	Molecular mechanisms of Bartonella henselae resistance to azithromycin, pradofloxacin and enrofloxacin.
18230686	J. Antimicrob. Chemother.	2008	Murphy BS et al.	Azithromycin alters macrophage phenotype.
18252692	J. Antimicrob. Chemother.	2008	Lucchi M et al.	Pharmacokinetics of azithromycin in serum, bronchial washings, alveolar macrophages and lung tissue following a single oral dose of extended or immediate release formulations of azithromycin.
18174195	J. Antimicrob. Chemother.	2008	Yanagihara K et al.	Subinhibitory concentrations of telithromycin, clarithromycin and azithromycin reduce methicillin-resistant Staphylococcus aureus coagulase in vitro and in vivo.
14998983	J. Antimicrob. Chemother.	2004	Carfartan G et al.	Effect of subinhibitory concentrations of azithromycin on adherence of Pseudomonas aeruginosa to bronchial mucins collected from cystic fibrosis patients.
15890718	J. Antimicrob. Chemother.	2005	Bouchillon SK et al.	Impact of carbon dioxide on the susceptibility of key respiratory tract pathogens to telithromycin and azithromycin.
15845780	J. Antimicrob. Chemother.	2005	Blessing E et al.	A 6 week course of azithromycin treatment has no beneficial effect on atherosclerotic lesion development in apolipoprotein E-deficient mice chronically infected with Chlamydia pneumoniae.
16002421	J. Antimicrob. Chemother.	2005	Girard D et al.	Enhanced efficacy of single-dose versus multi-dose azithromycin regimens in preclinical infection models.
16469851	J. Antimicrob. Chemother.	2006	Phaff SJ et al.	Macrolide resistance of Staphylococcus aureus and Haemophilus species associated with long-term azithromycin use in cystic fibrosis.
17110394	J. Antimicrob. Chemother.	2007	Moon JE et al.	Effect of timing and duration of azithromycin therapy of leptospirosis in a hamster model.
16617063	J. Antimicrob. Chemother.	2006	Sevillano D et al.	Azithromycin iv pharmacodynamic parameters predicting Streptococcus pneumoniae killing in epithelial lining fluid versus serum: an in vitro pharmacodynamic simulation.
16782744	J. Antimicrob. Chemother.	2006	Alou L et al.	A pharmacodynamic approach to antimicrobial activity in serum and epithelial lining fluid against in vivo-selected Streptococcus pneumoniae mutants and association with clinical failure in pneumonia.
18552343	J. Antimicrob. Chemother.	2008	Palmer HM et al.	Emergence and spread of azithromycin-resistant Neisseria gonorrhoeae in Scotland.
22577100	J. Antimicrob. Chemother.	2012	Padwal RS et al.	Effect of gastric bypass surgery on azithromycin oral bioavailability.
22604449	J. Antimicrob. Chemother.	2012	Whiley DM et al.	The ticking time bomb: escalating antibiotic resistance in Neisseria gonorrhoeae is a public health disaster in waiting.
23152483	J. Antimicrob. Chemother.	2013	Pereira R et al.	Combination therapy for gonorrhoea: in vitro synergy testing.
23248239	J. Antimicrob. Chemother.	2013	Cory TJ et al.	Azithromycin increases in vitro fibronectin production through interactions between macrophages and fibroblasts stimulated with Pseudomonas aeruginosa.